Financial Performance - Total revenue increased by 0.65% to RMB 933.6 million for the year ended December 31, 2025, compared to RMB 927.6 million in 2024[5] - Gross profit decreased by 6.53% to approximately RMB 410.9 million, resulting in a gross margin of 44.0%, down 3.4 percentage points from 47.4% in 2024[6] - Net loss narrowed to RMB 55.1 million, an improvement of approximately 9.12% from a net loss of RMB 60.7 million in the previous year[7] - The company reported a pre-tax loss of RMB 40.4 million, an improvement of 28.13% compared to a loss of RMB 56.2 million in the previous year[29] - The group reported a pre-tax loss of RMB 100,268 thousand for the current period, compared to a loss of RMB 105,799 thousand in the previous year[91] - The group reported a total tax expense of RMB 14,764,000 for 2025, a significant increase from RMB 4,491,000 in 2024[101] - The cumulative tax losses generated in mainland China as of December 31, 2025, amounted to RMB 888,229,803, compared to RMB 270,503,294 in 2024[102] - The basic and diluted loss per share for 2025 was RMB (5.92), slightly worse than RMB (5.77) in 2024[106] Revenue Growth Areas - The oncology segment revenue experienced a significant growth of 106.2%, driven by strategic acquisitions and market expansion[5] - The contract research organization (CRO) segment reported a revenue increase of 33.4% during the reporting period[5] - Revenue from tumor testing services surged by 106.2% year-on-year to RMB 44.8 million, becoming a significant growth driver[35] - The revenue from the research services and CRO segment increased by 33.4% to RMB 59.6 million, up from RMB 44.7 million in 2024[36] Strategic Initiatives - The company is focusing on high-level clinical research around its core technology for MRD monitoring, particularly in early-stage lung and breast cancers[10] - Strategic investments in new business segments and operational efficiency measures are showing positive results, stabilizing the operational fundamentals[7] - The company continues to optimize its business structure and expand into new markets despite external pressures from healthcare cost control policies[6] - The company plans to implement a dual-driven strategy focusing on "solid foundation and cutting-edge breakthroughs" to enhance its competitive edge in the evolving medical testing industry[27] - The company aims to strengthen its core specialties while leveraging the "IVD+LDT" dual-track synergy for resource optimization[27] Product Development and Innovation - In 2025, the company achieved a significant milestone with the commercial launch of its lung cancer early screening product, PulmoSeek®Plus, which completed the LDT filing process in collaboration with Guangzhou Medical University First Affiliated Hospital[11] - The UriFind® product for urinary tract cancer testing transitioned from early development to regular procurement, with over 200 hospitals in the development phase and more than 140 authorized hospitals, indicating strong clinical value and future revenue support[12] - The company expanded its non-invasive gastric cancer early detection product, Gastromia®, which received Class III medical device registration approval by the end of 2025, enhancing its comprehensive cancer management capabilities[12] - The company developed multiple high-precision testing projects, including MRD monitoring for acute myeloid leukemia and various genetic mutation tests for multiple myeloma, indicating advancements in its R&D capabilities[16] - The company published 13 research articles and applied for 56 patents in 2025, with 25 patents granted, including 6 invention patents, showcasing its commitment to innovation[15] Operational Efficiency - The company launched the "District Inspection Cloud V2.0" platform, enhancing operational efficiency and reducing error rates in sample testing[26] - The company completed a major upgrade of its T-cell immune function assessment product, increasing the detection capacity by 18 times, and achieved key breakthroughs in digital transformation[18] - The company has implemented strict controls over outstanding receivables to minimize credit risk, with senior management regularly reviewing overdue balances[114] Market Expansion and Partnerships - The company established over 100 new hospital partnerships in the hematology testing services, enhancing its market coverage[9] - The company added 41 new testing items and partnered with 83 new hospitals in the neurology sector, indicating a robust growth strategy in clinical collaboration and resource integration[13] - The company has established a sequencing center in New Zealand, expanding its global service capabilities and providing comprehensive long-read sequencing services[21] Financial Position and Investments - The company has a cash reserve of approximately RMB 1.88 billion as of December 31, 2025, supporting its strategic investments in multi-omics data integration and AI pathology analysis[25] - The company completed the acquisition of 100% equity interest in a target foreign-invested enterprise and 49% equity interest in a target U.S. company for a total consideration of approximately USD 31.30 million, with the transaction closing on January 24, 2025[61] - The company completed the acquisition of 90% equity in Shanghai ZhenGu Biotechnology Co., Ltd. for a total consideration of approximately RMB 20.5 million on March 17, 2026[67] Corporate Governance - The company is committed to maintaining strict corporate governance and has adopted the principles of the corporate governance code[141] - The board believes that the dual role of the chairman and CEO held by Dr. Wong does not affect the balance of power and responsibilities within the board[142] - The audit committee has reviewed the consolidated financial statements for the fiscal year ending December 31, 2025, confirming compliance with applicable accounting standards[144] - The board has proposed amendments to the Articles of Association to comply with the latest regulatory requirements, including provisions for a stock repurchase scheme[153] Shareholder Returns - The company has established a dividend policy, planning to distribute a total of at least HKD 300 million in cash dividends for the fiscal years 2025-2027, including approximately HKD 100 million for the fiscal year 2025[146] - The proposed final dividend for the year ending December 31, 2025, is HKD 0.095 per share, pending shareholder approval[103]

EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 康聖環球基因技術有限公司 | | 股份代號 | 09960 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止年度的末期股息 | | 公告日期 | 2026年3月27日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.095 HKD | | 股東批准日期 | 2026年6月5日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.095 HKD | | 匯 ...

Kindstar Globalgene Technology, Inc. 康聖環球基因技術有限公司 執行董事 黃士昂醫生 （主席兼首席執行官） 涂贊兵先生 柴海節女士 非執行董事 黃瑞瑨先生 彭偉先生 黃璐女士 王國瑋博士 獨立非執行董事 姚尚龍博士 夏新平博士 顧華明先生 王鋼博士 1 （於開曼群島註冊成立的有限公司） （股份代號：9960） 董事名單與其角色及職能 康聖環球基因技術有限公司（「本公司」）董事（「董事」）會（「董事會」）調整如下， 自2026年3月27日起生效。 董事會設立三個董事會委員會。下表載列各董事會成員在該等委員會中所擔任的 職位資料： | | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 黃士昂醫生 | | | C | | 涂贊兵先生 | | M | | | 柴海節女士 | | | | | 黃瑞瑨先生 | M | | | | 彭偉先生 | | | | | 黃璐女士 | | | M | | 王國瑋博士 | | | | | 姚尚龍博士 | | | M | | 夏新平博士 | C | M | M | | 顧華明先生 | M | C ...

Financial Performance - Total revenue increased by 0.65% to RMB 933.6 million for the year ended December 31, 2025, compared to RMB 927.6 million in 2024[5] - Gross profit decreased by 6.53% to approximately RMB 410.9 million, resulting in a gross margin of 44.0%, down 3.4 percentage points from 47.4% in 2024[6] - Net loss narrowed to RMB 55.1 million, an improvement of approximately 9.12% from a net loss of RMB 60.7 million in the previous year[7] - The revenue from hematology testing services, the core business, was RMB 563.1 million, showing a minor decline of 3.8% year-on-year[35] - The oncology testing services experienced significant growth, with revenue increasing by 106.2% to RMB 44.8 million, becoming a key growth driver[35] - The revenue from research services and CRO reached RMB 59.6 million, up 33.4% from RMB 44.7 million in 2024, driven by increased collaboration with hospitals and clients[36] - The group reported a total tax expense of RMB 14,764,000 for 2025, a significant increase from RMB 4,491,000 in 2024[101] - The pre-tax loss for 2025 was RMB (40,385,000), an improvement from RMB (56,190,000) in 2024[102] Business Segments and Growth - The oncology segment revenue experienced a significant growth of 106.2%, driven by strategic acquisitions and market expansion[5] - The contract research organization (CRO) segment reported a revenue increase of 33.4% during the reporting period[5] - The MRD testing business in the solid tumor sector achieved explosive growth, with revenue doubling year-on-year[10] - The company established over 100 new hospital partnerships in hematology, enhancing service coverage and operational continuity[9] - The company launched 131 new R&D testing projects in 2025, including 48 related to molecular biology and 21 related to flow cytometry, showcasing its commitment to innovation and industry leadership[15] - The LymScan® product for minimal residual disease (MRD) monitoring in hematological cancers saw a nearly 50% year-on-year revenue increase, reflecting its high clinical value and customer retention[18] Research and Development - The company successfully developed a personalized MRD product based on whole genome sequencing (WGS) targeting early-stage cancers[10] - The company completed the registration review for its non-invasive gastric cancer early detection product, Gastromia®, by the end of 2025, with approval for a Class III medical device in January 2026[12] - The company expanded its testing capabilities in neurology, adding 41 new testing items and collaborating with 83 new hospitals, enhancing regional medical resource integration[13] - The company has developed over 180 types of reagents, achieving a revenue growth of 76.8% year-on-year through precise alignment with clinical needs[19] Financial Position and Investments - The company has a cash reserve of approximately RMB 1.88 billion as of December 31, 2025, supporting future strategic investments[25] - The company completed the acquisition of 49% equity interest in a target U.S. company for a total consideration of approximately USD 31.30 million[61] - The company completed the acquisition of 100% equity in Guangzhou Kangcheng Weiye for approximately RMB 208 million, including RMB 148 million in cash and RMB 60 million worth of shares[82] - The total unutilized proceeds from the global offering is projected to be RMB 891.4 million as of December 31, 2025[69] Operational Efficiency - Strategic investments in new business segments and integration costs from acquisitions contributed to the operational efficiency improvements[7] - The launch of the "District Inspection Cloud V2.0" platform has improved operational efficiency and reduced error rates in sample testing[26] - The company continues to optimize its business structure and expand into new markets despite external pressures from healthcare cost control policies[6] Governance and Compliance - The company’s governance principles aim to maintain high standards of ethics, transparency, and accountability[141] - The audit committee has reviewed the consolidated financial statements for the fiscal year ending December 31, 2025, confirming compliance with applicable accounting standards[144] - The board has proposed amendments to the Articles of Association to comply with the latest regulatory requirements, including provisions for a stock repurchase system[153] Shareholder Returns - The proposed final dividend for the year ending December 31, 2025, is HKD 0.095 per share, pending shareholder approval[103] - The company has established a dividend policy, planning to distribute a total of at least HKD 300 million in cash dividends for the fiscal years 2025-2027, including approximately HKD 100 million for the fiscal year 2025[146] - The board has approved a three-year dividend guideline, which will be flexible based on market conditions and liquidity reserves, allowing adjustments between buybacks and dividends[146]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Kindstar Globalgene Technology, Inc. 康聖環球基因技術有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9960） 董事會召開日期 康聖環球基因技術有限公司（「本公司」及其附屬公司「本集團」）董事會（「董事 會」）茲通告謹定於二零二六年三月二十七日（星期五）舉行董事會會議，藉以考慮 及通過本集團截至二零二五年十二月三十一日止的綜合全年業績及其發佈，及考 處派發末期股息之建議（如有），以及處理其他事項。 承董事會命 康聖環球基因技術有限公司 主席 黃士昂 香港，2026年3月17日 截至本公告日期，董事會包括執行董事黃士昂醫生、涂贊兵先生及柴海節女士； 非執行董事黃瑞瑨先生、彭偉先生及黃璐女士；以及獨立非執行董事姚尚龍博 士、夏新平博士及顧華明先生。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康聖環球基因技術有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09960 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | 本月底法定/註冊 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康聖環球基因技術有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09960 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | 本月底法定/註冊 ...

Group 1 - The latest shareholder equity disclosure for Xin Da Holdings (08471) and Kang Sheng Global (09960) was conducted on January 30, 2026 [1] Group 2 - For Xin Da Holdings (08471), shareholder Xiao Fengcen reduced his holdings from 155 million shares to 54.77 million shares, resulting in a holding percentage decrease from 12.62% to 4.46% [2] - For Kang Sheng Global (09960), shareholder Mialkos Tomasz increased his holdings from 82.9235 million shares to 83.3085 million shares, maintaining a holding percentage of 8.00% [2] - Another shareholder, Jakub, had a previous holding percentage of 7.96% [2]

Group 1 - The core point of the news is that Mialkos Tomasz Jakub increased his stake in Kangsheng Global (09960.HK) by purchasing 385,000 shares at an average price of HKD 1.212 per share, resulting in a total investment of approximately HKD 466,600 [1] - After the purchase, Mialkos Tomasz Jakub's total shareholding increased to 83,308,500 shares, raising his ownership percentage from 7.96% to 8.00% [1][2]

Kindstar Globalgene Technology, Inc. 有關收購華西康聖達40%股權之關連交易之 補充公告 茲提述本公司日期為2025年11月25日之公告（「該公告」），內容有關收購華西康聖 達40%股權。除文義另有所指外，本公告所用詞彙與該公告所界定者具有相同涵 義。本公告旨在就收購華西康聖達40%股權之關連交易提供進一步資料。 量化指標的假設 康聖環球基因技術有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：9960） 以下為量化指標的假設。預測期取5年，即2025年至2029年。以後年度收益趨於 穩定，並假定與2029年相同（「穩定期」）。 收入增長率 華西康聖達主要客戶為合作醫院及其他第三方檢驗機構，通過提供血液、腫瘤等 特檢服務獲取收入。華西康聖達2020年至2024年的年均收入增長率約為5.45%。 受經濟形勢影響，2024年收入出現下降趨勢。為應對挑戰，2025年， ...